Valneva (NASDAQ:VALN) Reaches New 12-Month High - Here's Why

Key Points

• Valneva's stock reached a new 12-month high of $8.79, following a trading volume of 39,793 shares on Friday, compared to a previous close of $8.25.
• Analysts have mixed predictions, with Guggenheim reducing their price target from $15.00 to $14.00, while HC Wainwright maintained a $17.00 target and a "buy" rating.
• The company reported earnings per share of ($0.13), exceeding expectations significantly, along with quarterly revenue of $51.79 million, above analyst estimates of $41.80 million.

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) shares reached a new 52-week high during trading on Friday . The stock traded as high as $8.79 and last traded at $8.74, with a volume of 39793 shares trading hands. The stock had previously closed at $8.25.

Wall Street Analysts Forecast Growth

VALN has been the subject of several recent analyst reports. Guggenheim lowered their price target on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $17.00 price target on shares of Valneva in a report on Tuesday, April 15th.

Valneva Stock Up 10.4%

The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.12 and a current ratio of 2.70. The company has a market cap of $775.17 million, a PE ratio of -7.66 and a beta of 1.77. The firm has a fifty day simple moving average of $6.47 and a 200 day simple moving average of $6.58.

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.27. The business had revenue of $51.79 million for the quarter, compared to analyst estimates of $41.80 million. Valneva had a negative return on equity of 43.05% and a negative net margin of 43.08%. Equities research analysts predict that Valneva SE Sponsored ADR will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN increased its stake in shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) by 14.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 246,766 shares of the company's stock after acquiring an additional 30,859 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Valneva worth $1,079,000 at the end of the most recent reporting period. Institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.